Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
symbols : NVAX save search
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
Published: 2022-08-15 (Crawled : 13:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 3.86%
H: 1.6%
C: -0.42%
covid-19 fda for application authorization
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
Published: 2022-08-12 (Crawled : 14:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
covid-19 for vaccine approved
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -3.76%
H: 0.0%
C: 0.0%
results
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published: 2022-08-04 (Crawled : 13:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 0.31%
H: 3.16%
C: 1.03%
covid-19 global for children vaccine six trial
Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022
Published: 2022-08-01 (Crawled : 21:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -1.36%
H: 4.67%
C: 0.28%
conference results
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
Published: 2022-07-26 (Crawled : 12:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 0.53%
H: 6.0%
C: 2.08%
covid-19 australia for vaccine granted
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
Published: 2022-07-26 (Crawled : 12:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 0.53%
H: 6.0%
C: 2.08%
covid-19 for japan vaccine approval
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
Published: 2022-07-19 (Crawled : 21:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -0.16%
H: 11.38%
C: 2.87%
covid-19 for
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
Published: 2022-07-19 (Crawled : 13:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -4.39%
H: 13.25%
C: 10.02%
covid-19 vaccine agreement bioscience
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
Published: 2022-07-13 (Crawled : 22:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -4.42%
H: 2.36%
C: -22.79%
covid-19 fda for grants authorization emergency use authorization
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
Published: 2022-07-11 (Crawled : 12:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 2.85%
H: 1.68%
C: -9.36%
covid-19 vaccine
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Published: 2022-07-05 (Crawled : 14:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 8.77%
H: 13.79%
C: 13.27%
covid-19 for authorized vaccine
NOVAVAX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Novavax, Inc. - NVAX
Published: 2022-07-02 (Crawled : 04:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
| Email alert
Add to watchlist
initiated
Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants
Published: 2022-06-28 (Crawled : 23:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -2.27%
H: 6.45%
C: 3.91%
covid-19 fda antibody meeting prototype
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
Published: 2022-06-23 (Crawled : 19:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -0.06%
H: 0.5%
C: -0.21%
covid-19 for chmp vaccine authorization
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -4.23%
H: 3.34%
C: -6.74%
covid-19 australia vaccine
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
Published: 2022-06-07 (Crawled : 22:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 10.03%
H: 1.22%
C: -4.21%
covid-19 fda for vaccine authorization order emergency use authorization
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
Published: 2022-05-09 (Crawled : 22:00) - biospace.com/
TAK | $14.17 -0.49% 0.0% |
|
Health Technology
|
| O: -0.69%
H: 0.28%
C: -1.1%
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 0.09%
H: 5.27%
C: -7.13%
results
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
Published: 2022-05-02 (Crawled : 21:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: -0.38%
H: 19.8%
C: 19.71%
conference results
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
Published: 2022-04-29 (Crawled : 19:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% |
|
Health Technology
|
| O: 3.79%
H: 14.21%
C: -1.92%
covid-19 fda vaccine review
Top 10 Gainers
|
Retail Trade
AIM 4 | $0.742 -5.5% 6.47% |
|
Health Technology
AAMC | $20.0 1.27% 5.75% |
|
Finance
AINC 4 | $18.75 6.05% 5.71% |
|
Finance
AUD 4 | $0.7112 -2.52% 5.46% |
|
Information
A | $132.77 -0.84% 5.45% |
|
Health Technology
IDR | $5.9 -4.06% 5.42% |
|
n/a
INTT 4 | $9.77 -4.78% 5.22% |
|
Electronic Technology
EHAB P | $14.96 -5.91% 5.15% |
|
n/a
CINT | $13.68 -8.62% 5.12% |
|
Your saved searches
Save your searches and get alerts when important news are released.